Page 2 - Decipher Prostate News Today

Veracyte, Inc. announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as...

Operator: Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2023 Financial Results Webcast. At this time, all participants are in listen-only mode.

Detailed price information for Bausch Health Companies Inc (BHC-T) from The Globe and Mail including charting and trades.

Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial ... | May 2, 2023

Data from studies encompassing over 100,000 prostate cancer patients presented at American Urology Association 2023 Annual Meeting ... | April 29, 2023

SOUTH SAN FRANCISCO - Veracyte, Inc. announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who... | April 18, 2023

Findings published in European Urology Oncology suggest genomic classifier scores are highly correlated with PSMA PET upstaging of prostate cancer in those with high-risk and very high-risk disease ... | April 17, 2023

Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier ... | April 12, 2023

Operator: Good day and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2022 Financial Results Webcast. At this time, all participants are in a listen-only mode.

15.02.2023 - Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk ... Seite 1